The McPeak-Sirois Group and the Quebec Breast Cancer Foundation are pleased to announce the launch of the Accès-recherche program aimed at increasing access to clinical research in breast cancer for patients in all regions in Quebec.
Hence, the Accès-recherche Program of the McPeak-Sirois Group and the Quebec Breast Cancer Foundation aims to increase the number of hospital centres in Quebec participating in clinical trials (also called research protocols) in order to allow women, especially those living outside of major urban centers, access state-of-the-art treatments.
It is a unique endeavor in the fight against breast cancer in the province and a highly mobilizing pooling of efforts and skills from the research community in Quebec.
As a partner of the Accès-recherche Program, the Quebec Breast Cancer Foundation, that considers research as the cornerstone of its mission, has committed to deploy and financially support this innovative program by contributing $ 2.5 million over five years.
Susan McPeak, co-founder of the McPeak-Sirois Group, expresses her enthusiasm appreciating the initiative of the Group being supported by the Quebec Breast Cancer Foundation: “The support of the Quebec Breast Cancer Foundation is essential in the development of the Accès-recherche Program. We are grateful to the Foundation for giving us this unique opportunity to work hand in hand for the well-being of women affected by breast cancer.”
The Accès-recherche Program is in line with the mission of the two partners and maintains their commitment to increase access to state-of-the-art treatments for patients living in all regions in Quebec. For Nathalie Tremblay, CEO of the Quebec Breast Cancer Foundation, this is a huge step forward: “We truly believe in the outstanding research being conducted here in Quebec. The Quebec Breast Cancer Foundation is in fact the only philanthropic organisation to reinvest its funding only here, in this province. We therefore take great pride that the Foundation partners with the McPeak-Sirois Group for this program, which benefits in Quebec will be significant to all.”
This program will therefore promote an increased access to treatments and care considered as the most innovative for women stricken with breast cancer. As mentioned by Charles Sirois, Co-founder of the Group and Chairman of the Board: “This program was created to enable patients living in outlying areas in Quebec to have access to the same state-of-the-art treatments as those living in Montreal or Quebec City. In other words, it brings clinical research closer to patients by enabling regional hospitals to have access to the research trials carried out within of our Group”.
The McPeak-Sirois Group regroups the expertise of four major hospital research centres : The Jewish General Hospital (a member of the CIUSSS West-Central Montreal), the CHU de Québec – Université Laval, the McGill University Health Centre (MUHC), the Centre hospitalier de l’Université de Montréal (CHUM), and more recently, the Maisonneuve-Rosemont Hospital (CIUSSS-de-l’Est-de-l’Ile-de-Montréal). This unique collaboration between several major institutions is a breakthrough in clinical research in Canada.